Black Diamond Therapeutics (BDTX) EV to EBITDA (2020 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly EV to EBITDA came in at 0.35 in Q2 2026, up 169.15% on a YoY basis from 0.13 in Q2 2025, and up 204.1% quarter-over-quarter from 0.34 in Q1 2026.
Analysis
Black Diamond Therapeutics (BDTX) EV to EBITDA (2020 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported EV to EBITDA for 7 consecutive years, with 0.35 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EV to EBITDA rose 169.15% year-over-year to 0.35; the trailing twelve-month figure through Jun 2026 stood at 0.08 (up 121.92% YoY), and the FY2025 full-year result was 0.81, up 383.21% from the prior year.
- EV to EBITDA rose to 0.35 in Q2 2026 per BDTX's latest filing, from 0.34 in the prior quarter.
- Across five years, EV to EBITDA topped out at 3.74 in Q3 2022 and bottomed at 7.46 in Q1 2024.
- Historically, EV to EBITDA has averaged 1.26 across 5 years, with a median of 0.46 in 2025.
- The sharpest annual moves came in 2022 and 2024: EV to EBITDA soared 310.06% in 2022, then slumped 4380.58% in 2024.
- Over 5 years, EV to EBITDA stood at 2.62 in 2022, then tumbled by 125.13% to 0.66 in 2023, then tumbled by 88.29% to 1.24 in 2024, then soared by 53.28% to 0.58 in 2025, then soared by 160.61% to 0.35 in 2026.
- According to Business Quant data, EV to EBITDA over the past three periods registered 0.35, 0.34, and 0.58 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.35 |
| Mar 31, 2026 | -0.34 |
| Dec 31, 2025 | -0.58 |
| Sep 30, 2025 | -7.32 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | -1.18 |
| Dec 31, 2024 | -1.24 |
| Sep 30, 2024 | -7.35 |
| Jun 30, 2024 | -6.32 |
| Mar 31, 2024 | -7.46 |
| Dec 31, 2023 | -0.66 |
| Sep 30, 2023 | -0.16 |
| Jun 30, 2023 | -4.74 |
| Mar 31, 2023 | 1.59 |
| Dec 31, 2022 | 2.62 |
| Sep 30, 2022 | 3.74 |
| Jun 30, 2022 | 3.09 |
| Mar 31, 2022 | 3.09 |
| Dec 31, 2021 | 0.64 |
| Sep 30, 2021 | -2.02 |